Early in vivo antigens shaping virulence, immunity, and vaccines for cocci (coccidioidomycosis)
Official title: Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis
Funded at Northern Arizona University · NIH-11397284 · Data updated 2026-11-12
A multi-institution collaboration is studying how early antigens influence disease and vaccine responses to coccidioidomycosis in living systems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northern Arizona University NIH-funded |
| Lab location | 1 site (Flagstaff, United States) |
| Project start | August 24, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $235,897 |
| NIH project number | 5U19AI166058-05 |
| Project ID | NIH-11397284 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with or at risk for coccidioidomycosis who may benefit from improved vaccines or treatments.
✕Less likely to help
Individuals not involved in vaccine development or not at risk for cocci may see limited direct benefit.
What this research studies
This project is a collaborative effort across multiple universities to understand which early antigens drive the fungus’s virulence and the host immune response. It uses animal models and related studies to explore how these antigens could inform vaccine design. The administrative core manages cross-institution coordination, data sharing, and compliance to ensure efficient progress toward practical outcomes for patients. The research aims to build a foundation for better vaccines and therapies for people affected by coccidioidomycosis.
Why it matters
Potential benefit: If successful, this work could lead to more effective vaccines or therapies for people with cocci.
How similar studies have gone: Prior work in cocci vaccine development has shown promise, but translating early antigen findings into vaccines remains challenging and newer collaborative efforts are ongoing.
Where this research is happening
-
Northern Arizona University
Flagstaff, United States Active
Researchers
- Principal investigator: Keim, Paul Stephen — Northern Arizona University
- Study coordinator: Keim, Paul Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.